

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mark E. Duggan, et al.

Attorney Docket No. 21368YP

PCT Appl. No.: PCT/US04/012265 Filed: 20 April 2004

Filing Date: October 21, 2005

For: INHIBITORS OF AKT ACTIVITY

Art Unit:

To be determined

Examiner:

To be determined

Mail Stop: PCT  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

LETTER

Sir:

In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases: Application Disclosures Containing Nucleotide And/Or Amino Acid Sequences, the signature page and following statement are being submitted herewith.


I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

The enclosed diskette contains the Sequence Listing for case number 21368YP.

EXPRESS MAIL CERTIFICATE  
DATE OF DEPOSIT OCT. 21, 2005  
EXPRESS MAIL NO. 4242343205 US  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"  
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO  
COMMISSIONER FOR PATENTS, P.O. BOX 1450,  
ALEXANDRIA, VIRGINIA 22313-1450.  
MAILED BY Alexandra Zeller  
DATE October 21, 2005

Respectfully submitted,

By:

  
Matthew A. Leff  
Registration No. 50,149  
Attorney for Applicants

Merck & Co., Inc.  
P.O. Box 2000 - RY 60-30  
Rahway, New Jersey 07065-0907  
Telephone No. (732) 594-1404

Date: October 21, 2005